Y Intercept Hong Kong Ltd Invests $407,000 in Amphastar Pharmaceuticals, Inc. $AMPH

Y Intercept Hong Kong Ltd purchased a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 17,727 shares of the company’s stock, valued at approximately $407,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Millennium Management LLC increased its position in Amphastar Pharmaceuticals by 238.5% in the first quarter. Millennium Management LLC now owns 868,551 shares of the company’s stock worth $25,179,000 after buying an additional 611,995 shares during the period. TD Asset Management Inc grew its position in shares of Amphastar Pharmaceuticals by 20.2% during the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company’s stock worth $64,130,000 after acquiring an additional 371,856 shares during the last quarter. Royce & Associates LP increased its holdings in shares of Amphastar Pharmaceuticals by 2,684.3% in the 1st quarter. Royce & Associates LP now owns 247,858 shares of the company’s stock worth $7,185,000 after acquiring an additional 238,956 shares during the period. CX Institutional lifted its position in Amphastar Pharmaceuticals by 220.5% in the 2nd quarter. CX Institutional now owns 263,283 shares of the company’s stock valued at $6,045,000 after purchasing an additional 181,136 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its stake in Amphastar Pharmaceuticals by 14.5% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company’s stock valued at $36,565,000 after purchasing an additional 160,034 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on AMPH shares. Weiss Ratings restated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, October 8th. Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a report on Friday, August 8th. Bank of America lifted their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Zacks Research raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, Needham & Company LLC lowered their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $31.20.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $24.03 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $49.53. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of 9.00 and a beta of 0.77. The firm has a 50-day moving average of $26.23 and a two-hundred day moving average of $25.27.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.10. Amphastar Pharmaceuticals had a net margin of 18.64% and a return on equity of 20.76%. The company had revenue of $191.84 million for the quarter, compared to analysts’ expectations of $186.90 million. As a group, analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.